Charles Schwab Investment Management Inc. grew its holdings in Astrana Health, Inc. (NASDAQ:ASTH - Free Report) by 6.0% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 499,529 shares of the company's stock after acquiring an additional 28,200 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.89% of Astrana Health worth $15,490,000 at the end of the most recent reporting period.
Several other institutional investors have also added to or reduced their stakes in ASTH. Quarry LP boosted its holdings in Astrana Health by 35.5% in the fourth quarter. Quarry LP now owns 1,799 shares of the company's stock worth $57,000 after acquiring an additional 471 shares in the last quarter. US Bancorp DE boosted its holdings in Astrana Health by 21.3% in the first quarter. US Bancorp DE now owns 5,791 shares of the company's stock worth $180,000 after acquiring an additional 1,015 shares in the last quarter. PharVision Advisers LLC acquired a new stake in Astrana Health in the fourth quarter worth about $211,000. Envestnet Asset Management Inc. boosted its holdings in Astrana Health by 19.9% in the fourth quarter. Envestnet Asset Management Inc. now owns 7,124 shares of the company's stock worth $225,000 after acquiring an additional 1,184 shares in the last quarter. Finally, City Center Advisors LLC acquired a new stake in Astrana Health in the first quarter worth about $276,000. Institutional investors and hedge funds own 52.77% of the company's stock.
Astrana Health Trading Up 2.4%
Astrana Health stock opened at $30.68 on Friday. The company has a quick ratio of 1.59, a current ratio of 1.59 and a debt-to-equity ratio of 0.52. Astrana Health, Inc. has a 52 week low of $21.20 and a 52 week high of $63.20. The company has a market capitalization of $1.72 billion, a price-to-earnings ratio of 60.16, a price-to-earnings-growth ratio of 0.74 and a beta of 0.85. The stock has a 50-day moving average price of $25.26 and a 200 day moving average price of $28.67.
Astrana Health (NASDAQ:ASTH - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported $0.19 EPS for the quarter, missing analysts' consensus estimates of $0.36 by ($0.17). Astrana Health had a return on equity of 3.43% and a net margin of 1.04%.The firm had revenue of $654.81 million for the quarter, compared to analyst estimates of $639.13 million. During the same period last year, the firm earned $0.40 EPS. The company's revenue for the quarter was up 34.7% compared to the same quarter last year. Astrana Health has set its Q3 2025 guidance at EPS. Sell-side analysts anticipate that Astrana Health, Inc. will post 1.15 EPS for the current year.
Astrana Health Company Profile
(
Free Report)
Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.
Further Reading
Want to see what other hedge funds are holding ASTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrana Health, Inc. (NASDAQ:ASTH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Astrana Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Astrana Health wasn't on the list.
While Astrana Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.